Atalanta Therapeutics

Atalanta Therapeutics

  • Founded: 2018
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Huntington's disease
  • Drug types: NEU, GEN
  • Lead product: Undisclosed
  • Product link:
  • Funding: $110M A Jan 2021

job board

Short description:

RNAi therapeutics

Drug notes:

Undisclosed programs RD Parkinson's, Alzheimer's, other neurodegenerative diseases

Long description:

Atalanta Therapeutics is using RNA interference (RNAi) technologies to find treatments for neurodegenerative diseases. RNAi is a natural process cells use to silence gene activity that can be employed as a strategy to target and silence disease-causing genes such as those driving neurological diseases. A major limitation of RNAi has been delivery of the technology to the central nervous system to target cells. Atalanta has developed their proprietary RNAi that uses their branched siRNA and enables RNAi to be deployed as a therapeutic approach throughout the brain and spinal cord. The branched siRNA has a common scaffold that supports delivery, but can also be customized at the nucleotide level to target different genes. Atalanta is currently focusing on Huntington’s disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy